Literature DB >> 8642867

Proliferation of B cell malignancies in all stages of differentiation upon stimulation in the 'CD40 system'.

E V Planken1, N H Dijkstra, R Willemze, J C Kluin-Nelemans.   

Abstract

Stimulation of the CD40 antigen on normal B cells by crosslinking of anti-CD40 mAbs via their Fc receptor using a Fc gamma RII(CD32)-transfected mouse fibroblast cell line ('CD40 system') results in activation and proliferation. Not only normal B cells, but also malignant B cells fitting in the low-grade malignancy category such as chronic lymphocytic leukemia (CLL), hairy cell leukemia and follicular lymphoma could be induced to proliferation upon CD40 stimulation. Here, the 'CD40 system' has also been used to culture intermediate and high grade malignancies. Proliferation was measured by 3H-thymidine incorporation and cell counting after culture. Time curves showed that at day 7 most cultures were optimal. By flow cytometry, morphology and assessment of light chain restriction the monoclonal nature of the cultured B cells was proven. We confirmed that B cell malignancies with a more slowly evolving course, such as CLL (n=11), PLL (n=5), and low-grade NHL (immunocytoma and follicular cb/cc n=9), could successfully be cultured in the 'CD40 system'. In contrast, four out of seven cases of mantle cell lymphoma did not proliferate. Cases of precursor B lineage ALL (n=7), high grade NHL (n=3) and multiple myeloma (n=10) showed a heterogenous growth pattern. We conclude that the 'CD40 system', although not always successful, is a useful tool to culture a whole variety of B cell malignancies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8642867

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  9 in total

1.  The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells.

Authors:  Mohammad Luqman; Sha Klabunde; Karen Lin; Georgios V Georgakis; Anu Cherukuri; Jocelyn Holash; Cheryl Goldbeck; Xiaomei Xu; Edward E Kadel; Sang Hoon Lee; Sharon Lea Aukerman; Bahija Jallal; Natasha Aziz; Wen-Kai Weng; William Wierda; Susan O'Brien; Anas Younes
Journal:  Blood       Date:  2008-05-22       Impact factor: 22.113

Review 2.  Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications.

Authors:  Daisuke Ito; Aric M Frantz; Jaime F Modiano
Journal:  Vet Immunol Immunopathol       Date:  2014-02-24       Impact factor: 2.046

3.  Aberrant B cell receptor signaling from B29 (Igbeta, CD79b) gene mutations of chronic lymphocytic leukemia B cells.

Authors:  M S Gordon; R M Kato; F Lansigan; A A Thompson; R Wall; D J Rawlings
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

4.  CD40·FasL and CTLA-4·FasL fusion proteins induce apoptosis in malignant cell lines by dual signaling.

Authors:  Ariel Orbach; Jacob Rachmilewitz; Noam Shani; Yonatan Isenberg; Miriam Parnas; Jui-Han Huang; Mark L Tykocinski; Michal Dranitzki-Elhalel
Journal:  Am J Pathol       Date:  2010-11-18       Impact factor: 4.307

5.  CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: a tool for in vitro preclinical studies with primary B-cell malignancies.

Authors:  Daisuke Ito; Aric M Frantz; Christina Williams; Rachael Thomas; Robert C Burnett; Anne C Avery; Matthew Breen; Nicola J Mason; Timothy D O'Brien; Jaime F Modiano
Journal:  Leuk Lymphoma       Date:  2012-02-03

6.  CD40 ligand induces RIP1-dependent, necroptosis-like cell death in low-grade serous but not serous borderline ovarian tumor cells.

Authors:  X Qiu; C Klausen; J-C Cheng; P C K Leung
Journal:  Cell Death Dis       Date:  2015-08-27       Impact factor: 8.469

7.  Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk.

Authors:  Lavanya Lokhande; Venera Kuci Emruli; Arne Kolstad; Martin Hutchings; Riikka Räty; Mats Jerkeman; Sara Ek
Journal:  BMC Cancer       Date:  2020-12-07       Impact factor: 4.430

8.  Fas-associated factor (Faf1) is a novel CD40 interactor that regulates CD40-induced NF-κB activation via a negative feedback loop.

Authors:  T Elmetwali; L S Young; D H Palmer
Journal:  Cell Death Dis       Date:  2014-05-08       Impact factor: 8.469

9.  CD40L membrane retention enhances the immunostimulatory effects of CD40 ligation.

Authors:  Taha Elmetwali; Asmaa Salman; Wenbin Wei; Syed A Hussain; Lawrence S Young; Daniel H Palmer
Journal:  Sci Rep       Date:  2020-01-15       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.